Related Experiment Video
Updated: Jul 17, 2026
04:22
Biomarker Identification for Gender Specificity of Alzheimer's Disease Based on the Glial Transcriptome Profiles
Published on: May 20, 2024
Biological markers in Alzheimer's disease
I Grundke-Iqbal1, G Rolkova, E Konstekova
1New York State Institute for Basic Research in Developmental Disabilities, Staten Island, New York 10314, USA.
Bratislavske Lekarske Listy
|February 1, 2007
Summary
Accurate Alzheimer's disease (AD) diagnosis requires reliable biomarkers. Current protein and genetic markers show promise but are insufficient for definitive diagnosis due to AD's complexity.
Area of Science:
- Neuroscience
- Biochemistry
- Genetics
Background:
- Alzheimer's disease (AD) is the leading cause of dementia, clinically marked by memory loss and pathologically by neurofibrillary tangles and senile plaques.
- Current clinical diagnosis accuracy for AD varies significantly (60-95%), leading to misdiagnoses.
- There is a critical need for biological markers to accurately distinguish AD patients from non-AD individuals.
Purpose of the Study:
- To review existing and potential biological markers for Alzheimer's disease diagnosis.
- To highlight the limitations of current biomarkers in definitively diagnosing AD.
- To emphasize the importance of identifying AD subgroups for improved diagnosis and therapeutics.
Main Methods:
- Review of current literature on Alzheimer's disease biomarkers.
- Categorization of biomarkers into protein and genetic markers.
- Discussion of specific protein markers (tau, ubiquitin, amyloid beta-peptides) and genetic markers (apolipoprotein E, APP, presenilin genes).
Main Results:
- Key protein biomarkers in cerebrospinal fluid include tau proteins, ubiquitin, and amyloid beta-peptides.
- Significant genetic markers for AD involve the apolipoprotein E gene and mutations in amyloid precursor protein and presenilin genes.
- Existing biomarkers do not allow for definitive AD diagnosis due to the multifactorial and heterogeneous nature of the disease.
Conclusions:
- Further identification of Alzheimer's disease subgroups is essential for enhancing diagnostic accuracy.
- Understanding AD heterogeneity is crucial for the development of effective therapeutic strategies.
- Development of unambiguous biological markers remains a priority for reliable AD diagnosis.
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.